Reference health

Low Energy Electron Irradiation Is a Potent Alternative to Gamma Irradiation for the Inactivation of (CAR-)NK-92 Cells in ATMP Manufacturing

https://doi.org/10.3389/fimmu.2021.684052
CiteStamped reference-health badge
59/59 checkable references clean · checked 2026-07-23

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

2 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.

The 59 checked references that resolve
resolves10.1007/s00262-015-1761-x
NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy
resolves10.1159/000495771
CAR-Expressing Natural Killer Cells for Cancer Retargeting
resolves10.3390/cancers11091358
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
resolves10.1007/s12185-019-02616-y
Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia
resolves10.1158/1078-0432.CCR-16-1904
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia
resolves10.18632/oncotarget.26118
Survival outcomes of CD34+CD38−LSCs and their expression of CD123 in adult AML patients
resolves10.1089/hum.2018.247
Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer–Based “Off-the-Shelf” Acute Myeloid Leukemia Immunotherapies
resolves10.3389/fimmu.2015.00578
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
resolves10.3389/fimmu.2017.00533
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
resolves10.1080/14653240802301872
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
resolves10.1016/j.jcyt.2013.06.017
Treatment of patients with advanced cancer with the natural killer cell line NK-92
resolves10.1016/j.freeradbiomed.2012.04.033
Ionizing radiation induces mitochondrial reactive oxygen species production accompanied by upregulation of mitochondrial electron transport chain function and mitochondrial content under control of the cell cycle checkpoint
resolves10.1186/s12967-017-1338-x
Radioprotective agents to prevent cellular damage due to ionizing radiation
resolves10.3390/ijms17010102
Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization
resolves10.1128/AEM.00081-11
Inactivation of a Human Norovirus Surrogate, Human Norovirus Virus-Like Particles, and Vesicular Stomatitis Virus by Gamma Irradiation
resolves10.3389/fimmu.2017.00613
Modulating Both Tumor Cell Death and Innate Immunity Is Essential for Improving Radiation Therapy Effectiveness
resolves10.1186/s40779-018-0167-4
Biological effects of radiation on cancer cells
resolves10.1038/s41598-020-69347-7
Automated application of low energy electron irradiation enables inactivation of pathogen- and cell-containing liquids in biomedical research and production facilities
resolves10.1016/j.radphyschem.2018.04.008
Low-energy electron-beam treatment as alternative for on-site sterilization of highly functionalized medical products – A feasibility study
resolves10.3390/v8110319
Pathogens Inactivated by Low-Energy-Electron Irradiation Maintain Antigenic Properties and Induce Protective Immune Responses
resolves10.1007/s00109-015-1327-6
Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors
resolves10.1088/1742-6596/151/1/012022
Quartz-Containing Ceramic Dusts:<i>In vitro</i>screening of the cytotoxic, genotoxic and pro-inflammatory potential of 5 factory samples
resolves10.1186/s13104-016-1900-2
AdapterRemoval v2: rapid adapter trimming, identification, and read merging
resolves10.1038/s41587-019-0201-4
Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
resolves10.1093/nar/gky955
GENCODE reference annotation for the human and mouse genomes
resolves10.1093/bioinformatics/btu638
HTSeq—a Python framework to work with high-throughput sequencing data
resolves10.1186/s12859-019-3219-1
uap: reproducible and robust HTS data analysis
resolves10.1186/s13059-014-0550-8
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
resolves10.1093/nar/gkz1031
The reactome pathway knowledgebase
resolves10.1039/C5MB00663E
ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization
resolves10.1089/omi.2011.0118
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
resolves10.3389/fimmu.2017.00892
CD56 in the Immune System: More Than a Marker for Cytotoxicity?
resolves10.1038/ncomms12171
Human NK cell development requires CD56-mediated motility and formation of the developmental synapse
resolves10.1385/1-59259-788-2:051
Analyzing the G2/M Checkpoint
resolves10.3389/fimmu.2018.00283
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
resolves10.1007/s00262-017-2055-2
Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies
resolves10.1038/mt.2014.219
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
resolves10.1089/10430349950018030
Characterization of Genetically Altered, Interleukin 2-Independent Natural Killer Cell Lines Suitable for Adoptive Cellular Immunotherapy
resolves10.1093/jnci/djv375
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
resolves10.18632/oncotarget.13411
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
resolves10.1016/j.jcyt.2020.06.003
Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19+ malignancy in a mouse model
resolves10.3390/cells9061382
Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer
resolves10.1016/j.molonc.2013.12.001
Transfection of chimeric anti‐CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells
resolves10.3324/haematol.2017.187385
CD16<sup>+</sup>NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice
resolves10.1089/106161299320316
Immunotherapy of Malignant Melanoma in a SCID Mouse Model Using the Highly Cytotoxic Natural Killer Cell Line NK-92
resolves10.18632/oncotarget.19204
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
resolves10.1016/j.ajpath.2013.02.041
IFN-γ Mediates the Antitumor Effects of Radiation Therapy in a Murine Colon Tumor
resolves10.3389/fonc.2013.00118
Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol
resolves10.1016/s1471-4906(01)02060-9
The biology of human natural killer-cell subsets
resolves10.1038/s41423-018-0163-3
Shining light on the significance of NK cell CD56 brightness
resolves10.1002/ijc.30767
ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody
resolves10.1385/1-59259-671-1:1
The ERK Cascade As a Prototype of MAPK Signaling Pathways
resolves10.1210/en.2014-1709
GnRH Regulates Gonadotropin Gene Expression Through NADPH/Dual Oxidase-Derived Reactive Oxygen Species
resolves10.3390/ijms20236092
DNA Oxidation and Excision Repair Pathways
resolves10.1038/leu.2013.279
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
resolves10.1038/srep11483
CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
resolves10.1155/2017/6915912
Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
resolves10.1155/2018/4263520
Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
resolves10.1007/s00262-015-1669-5
Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma
The 2 references without a DOI — listed, not checked
no DOI — not checkedSterilization of Surgical Instruments Using Mini Electron Accelerators: In Proceedings of the 52nd Annual Technical Conference 2009
no DOI — not checkedCharacterization of a Human Cell Line (NK-92) With Phenotypical and Functional Characteristics of Activated Natural Killer Cells
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.3389/fimmu.2021.684052"><img src="https://citestamp.com/citestamped/10.3389/fimmu.2021.684052/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.3389/fimmu.2021.684052/badge.svg)](https://citestamp.com/citestamped/10.3389/fimmu.2021.684052)